Cognitive impairments in the STOP null mouse model of schizophrenia
- PMID: 17907815
- DOI: 10.1037/0735-7044.121.5.826
Cognitive impairments in the STOP null mouse model of schizophrenia
Abstract
Cognitive dysfunction is a primary and persisting core deficit of schizophrenia that is marginally improved by antipsychotic treatment. Adult mice that lack the stable tubule-only polypeptide (STOP) have neurochemical and behavioral abnormalities that model some features of schizophrenia. Recognition and long-term memory in the STOP null mouse were tested with the novel object recognition task and an olfactory discrimination task, respectively. Researchers examined the brains from STOP null mice to determine whether differences in task performance were associated with alterations in brain morphology. STOP null mice displayed deficits in both recognition and long-term memory. These behavioral deficits were accompanied by a massive enlargement of the cerebral ventricular system as well as by reductions in volume of cortical and diencephalic structures. In addition to deficits in recognition and long-term memory, STOP null mice displayed exaggerated neuroanatomical deficits somewhat reminiscent of those observed among individuals with schizophrenia.
(PsycINFO Database Record (c) 2007 APA, all rights reserved).
Similar articles
-
The stop null mice model for schizophrenia displays [corrected] cognitive and social deficits partly alleviated by neuroleptics.Neuroscience. 2008 Nov 11;157(1):29-39. doi: 10.1016/j.neuroscience.2008.07.080. Epub 2008 Aug 29. Neuroscience. 2008. PMID: 18804150
-
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.Peptides. 2010 Jul;31(7):1368-73. doi: 10.1016/j.peptides.2010.04.011. Epub 2010 Apr 22. Peptides. 2010. PMID: 20417241
-
Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice.J Psychopharmacol. 2007 Aug;21(6):635-44. doi: 10.1177/0269881106068825. Epub 2006 Oct 18. J Psychopharmacol. 2007. PMID: 17050659
-
Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia.Neurosci Biobehav Rev. 2005;29(6):913-47. doi: 10.1016/j.neubiorev.2004.10.012. Neurosci Biobehav Rev. 2005. PMID: 15964075 Review.
-
[A role for microtubules in mental diseases?].Pathol Biol (Paris). 2004 Mar;52(2):89-92. doi: 10.1016/j.patbio.2003.04.007. Pathol Biol (Paris). 2004. PMID: 15001237 Review. French.
Cited by
-
Subchronic oral administration of crude khat extract (Catha edulis forsk) induces schizophernic-like symptoms in mice.BMC Complement Altern Med. 2016 May 31;16:153. doi: 10.1186/s12906-016-1145-6. BMC Complement Altern Med. 2016. PMID: 27245332 Free PMC article.
-
Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice.Psychopharmacology (Berl). 2010 Jan;208(1):131-41. doi: 10.1007/s00213-009-1712-3. Epub 2009 Nov 21. Psychopharmacology (Berl). 2010. PMID: 19936716 Free PMC article.
-
Nitric oxide synthase mediates the ability of darbepoetin alpha to improve the cognitive performance of STOP null mice.Neuropsychopharmacology. 2010 Jul;35(8):1718-28. doi: 10.1038/npp.2010.36. Epub 2010 Mar 24. Neuropsychopharmacology. 2010. PMID: 20336057 Free PMC article.
-
Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies.Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:83-91. doi: 10.1016/j.pnpbp.2014.05.001. Epub 2014 May 10. Prog Neuropsychopharmacol Biol Psychiatry. 2014. PMID: 24819820 Free PMC article.
-
Loss of STOP protein impairs peripheral olfactory neurogenesis.PLoS One. 2010 Sep 15;5(9):e12753. doi: 10.1371/journal.pone.0012753. PLoS One. 2010. PMID: 20856814 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical